2001. Letter by Suwa et al Regarding Article, "Safety of Switching From a Vitamin K Antagonist to a Non-Vitamin K Antagonist Oral Anticoagulant in Frail Older Patients With Atrial Fibrillation: Results of the FRAIL-AF Randomized Controlled Trial".2002. Letter by Millis et al Regarding Article, "Safety of Switching From a Vitamin K Antagonist to a Non-Vitamin K Antagonist Oral Anticoagulant in Frail Older Patients With Atrial Fibrillation: Results of the FRAIL-AF Randomized Controlled Trial".2003. Letter by Lin Regarding Article, "Safety of Switching from a Vitamin K Antagonist to a Non-Vitamin K Antagonist Oral Anticoagulant in Frail Older Patients with Atrial Fibrillation: Results of the FRAIL-AF Randomized Controlled Trial".2004. Letter by Kohsaka et al Regarding Article, "Safety of Switching From a Vitamin K Antagonist to a Non-Vitamin K Antagonist Oral Anticoagulant in Frail Older Patients With Atrial Fibrillation: Results of the FRAIL-AF Randomized Controlled Trial".2005. Culprit-Only Revascularization, Single-Setting Complete Revascularization, and Staged Complete Revascularization in Acute Myocardial Infarction: Insights From a Mixed Treatment Comparison Meta-Analysis of Randomized Trials.
作者: Muhammad Haisum Maqsood.;Jacqueline E Tamis-Holland.;Sunil V Rao.;Gregg W Stone.;Sripal Bangalore.
来源: Circ Cardiovasc Interv. 2024年17卷7期e013737页
Complete revascularization improves cardiovascular outcomes compared with culprit-only revascularization in patients with acute myocardial infarction ([MI]; ST-segment-elevation MI or non-ST-segment-elevation MI) and multivessel coronary artery disease. However, the timing of complete revascularization (single-setting versus staged revascularization) is uncertain. The aim was to compare the outcomes of single-setting complete, staged complete, and culprit vessel-only revascularization in patients with acute MI and multivessel disease.
2006. Letter by Highton and Khunti Regarding Article, "Pragmatic Trial of Messaging to Providers About Treatment of Hyperlipidemia (PROMPT-LIPID): A Randomized Clinical Trial".2008. Atrioventricular Synchrony Delivered by a Dual-Chamber Leadless Pacemaker System.
作者: James E Ip.;Mayer Rashtian.;Derek V Exner.;Vivek Y Reddy.;Rahul Doshi.;Nima Badie.;Jordan R Nevo.;Aditya Goil.;Pascal Defaye.;Robert Canby.;Maria Grazia Bongiorni.;Morio Shoda.;Gerhard Hindricks.;Reinoud E Knops.
来源: Circulation. 2024年150卷6期439-450页
A dual-chamber leadless pacemaker system has been designed for atrioventricular synchronous pacing using wireless, beat-to-beat, implant-to-implant (i2i) communication between distinct atrial and ventricular leadless pacemakers. The atrioventricular synchrony achieved across various ambulatory scenarios has yet to be systematically evaluated.
2009. Graft Patency and Clinical Outcomes in Patients With Radial Artery Grafts Previously Instrumented for Cardiac Catheterization.
作者: Garry W Hamilton.;James Theuerle.;David Chye.;Jayapadman Bhaskar.;Siven Seevanayagam.;Hannah Johns.;Leonid Churilov.;Julian Yeoh.;Matias B Yudi.;Louise Brown.;Jaishankar Raman.;David J Clark.;David L Hare.;Omar Farouque.
来源: Circ Cardiovasc Interv. 2024年17卷7期e013739页
While transradial access is favored for cardiac catheterization, the radial artery (RA) is increasingly preferred for coronary artery bypass grafting. Whether the RA is suitable for use as a graft following instrumentation for transradial access remains uncertain.
2011. Excess Mortality and Loss of Life Expectancy After Myocardial Infarction: A Registry-Based Matched Cohort Study.
作者: Christian Reitan.;Pontus Andell.;Joakim Alfredsson.;David Erlinge.;Robin Hofmann.;Bertil Lindahl.;Moa Simonsson.;Paul W Dickman.;Tomas Jernberg.
来源: Circulation. 2024年150卷11期826-835页
The effect of myocardial infarction (MI) on life expectancy is difficult to study because the prevalence of MI hinders direct comparison with the life expectancy of the general population. We sought to assess this in relation to age, sex, and left ventricular ejection fraction (LVEF) by comparing individuals with MI with matched comparators without previous MI.
2012. Rare Variant in MRC2 Associated With Familial Supraventricular Tachycardia and Wolff-Parkinson-White Syndrome.
作者: Adam S Potter.;Christina Y Miyake.;Claudia Gonzaga-Jauregui.;Yuriana Aguilar-Sanchez.;Mohit M Hulsurkar.;Satadru K Lahiri.;Lucia M Moreira.;Neelam Mehta.;Mahshid S Azamian.;James R Lupski.;Svetlana Reilly.;Seema R Lalani.;Xander H T Wehrens.
来源: Circ Genom Precis Med. 2024年17卷4期e004614页
Accessory pathways are a common cause of supraventricular tachycardia (SVT) and can lead to sudden cardiac death in otherwise healthy children and adults when associated with Wolff-Parkinson-White syndrome. The goal of this study was to identify genetic variants within a large family with structurally normal hearts affected by SVT and Wolff-Parkinson-White syndrome and determine causality of the gene deficit in a corresponding mouse model.
2013. Multisite Validation of a Functional Assay to Adjudicate SCN5A Brugada Syndrome-Associated Variants.
作者: Joanne G Ma.;Matthew J O'Neill.;Ebony Richardson.;Kate L Thomson.;Jodie Ingles.;Ayesha Muhammad.;Joseph F Solus.;Giovanni Davogustto.;Katherine C Anderson.;M Benjamin Shoemaker.;Andrew B Stergachis.;Brendan J Floyd.;Kyla Dunn.;Victoria N Parikh.;Henry Chubb.;Mark J Perrin.;Dan M Roden.;Jamie I Vandenberg.;Chai-Ann Ng.;Andrew M Glazer.
来源: Circ Genom Precis Med. 2024年17卷4期e004569页
Brugada syndrome is an inheritable arrhythmia condition that is associated with rare, loss-of-function variants in SCN5A. Interpreting the pathogenicity of SCN5A missense variants is challenging, and ≈79% of SCN5A missense variants in ClinVar are currently classified as variants of uncertain significance. Automated patch clamp technology enables high-throughput functional studies of ion channel variants and can provide evidence for variant reclassification.
2015. Correction to: Early Versus Late Initiation of Direct Oral Anticoagulants After Ischemic Stroke in People With Atrial Fibrillation and Hemorrhagic Transformation: Prespecified Subanalysis of the Randomized Controlled ELAN Trial.
来源: Circulation. 2024年150卷1期e20页
2016. Response by Berry et al to Letter Regarding Article, "Invasive Endotyping in Patients With Angina and No Obstructive Coronary Artery Disease: A Randomized Controlled Trial".2019. Apolipoprotein B: Bridging the Gap Between Evidence and Clinical Practice.
作者: Diana De Oliveira-Gomes.;Parag H Joshi.;Eric D Peterson.;Anand Rohatgi.;Amit Khera.;Ann Marie Navar.
来源: Circulation. 2024年150卷1期62-79页
Despite data suggesting that apolipoprotein B (apoB) measurement outperforms low-density lipoprotein cholesterol level measurement in predicting atherosclerotic cardiovascular disease risk, apoB measurement has not become widely adopted into routine clinical practice. One barrier for use of apoB measurement is lack of consistent guidance for clinicians on how to interpret and apply apoB results in clinical context. Whereas guidelines have often provided clear low-density lipoprotein cholesterol targets or triggers to initiate treatment change, consistent targets for apoB are lacking. In this review, we synthesize existing data regarding the epidemiology of apoB by comparing guideline recommendations regarding use of apoB measurement, describing population percentiles of apoB relative to low-density lipoprotein cholesterol levels, summarizing studies of discordance between low-density lipoprotein cholesterol and apoB levels, and evaluating apoB levels in clinical trials of lipid-lowering therapy to guide potential treatment targets. We propose evidence-guided apoB thresholds for use in cholesterol management and clinical care.
|